Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 1
1998 1
1999 1
2000 1
2001 2
2002 3
2003 3
2004 5
2005 3
2006 4
2007 8
2008 10
2009 13
2010 20
2011 27
2012 21
2013 26
2014 24
2015 22
2016 20
2017 24
2018 20
2019 27
2020 37
2021 44
2022 41
2023 42
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

389 results

Results by year

Filters applied: . Clear all
Page 1
CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor.
Prokhnevska N, Cardenas MA, Valanparambil RM, Sobierajska E, Barwick BG, Jansen C, Reyes Moon A, Gregorova P, delBalzo L, Greenwald R, Bilen MA, Alemozaffar M, Joshi S, Cimmino C, Larsen C, Master V, Sanda M, Kissick H. Prokhnevska N, et al. Among authors: master v. Immunity. 2023 Jan 10;56(1):107-124.e5. doi: 10.1016/j.immuni.2022.12.002. Epub 2022 Dec 28. Immunity. 2023. PMID: 36580918 Free PMC article.
Editorial Comment.
Master VA, Nicaise E. Master VA, et al. J Urol. 2023 Nov;210(5):760-761. doi: 10.1097/JU.0000000000003650.02. Epub 2023 Aug 23. J Urol. 2023. PMID: 37610970 No abstract available.
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.
Jansen CS, Prokhnevska N, Master VA, Sanda MG, Carlisle JW, Bilen MA, Cardenas M, Wilkinson S, Lake R, Sowalsky AG, Valanparambil RM, Hudson WH, McGuire D, Melnick K, Khan AI, Kim K, Chang YM, Kim A, Filson CP, Alemozaffar M, Osunkoya AO, Mullane P, Ellis C, Akondy R, Im SJ, Kamphorst AO, Reyes A, Liu Y, Kissick H. Jansen CS, et al. Among authors: master va. Nature. 2019 Dec;576(7787):465-470. doi: 10.1038/s41586-019-1836-5. Epub 2019 Dec 11. Nature. 2019. PMID: 31827286 Free PMC article.
Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline.
Mao JJ, Ismaila N, Bao T, Barton D, Ben-Arye E, Garland EL, Greenlee H, Leblanc T, Lee RT, Lopez AM, Loprinzi C, Lyman GH, MacLeod J, Master VA, Ramchandran K, Wagner LI, Walker EM, Bruner DW, Witt CM, Bruera E. Mao JJ, et al. Among authors: master va. J Clin Oncol. 2022 Dec 1;40(34):3998-4024. doi: 10.1200/JCO.22.01357. Epub 2022 Sep 19. J Clin Oncol. 2022. PMID: 36122322 Free article.
Optimizing cystectomy outcomes.
Porten SP, Master VA. Porten SP, et al. Among authors: master va. Cancer. 2019 Oct 15;125(20):3502-3503. doi: 10.1002/cncr.32359. Epub 2019 Jul 12. Cancer. 2019. PMID: 31299088 Free article. No abstract available.
In Reply.
Bilen MA, Master VA, Harvey RD. Bilen MA, et al. Among authors: master va. Oncologist. 2020 May;25(5):e876. doi: 10.1634/theoncologist.2020-0059. Epub 2020 Mar 23. Oncologist. 2020. PMID: 32201999 Free PMC article.
Schmeusser BN, Nicaise EH, Ogan K, Master VA. Schmeusser BN, et al. Among authors: master va. Urology. 2024 Jan;183:155-156. doi: 10.1016/j.urology.2023.07.052. Epub 2023 Nov 18. Urology. 2024. PMID: 37985283 No abstract available.
Nabavizadeh R, Higgins MI, Master VA, Ogan K. Nabavizadeh R, et al. Among authors: master va. Urology. 2021 Feb;148:124-125. doi: 10.1016/j.urology.2020.09.052. Urology. 2021. PMID: 33549204 No abstract available.
Reply by Authors.
Nicaise EH, Schmeusser BN, Patil DH, Ogan K, Master VA. Nicaise EH, et al. Among authors: master va. Urol Pract. 2023 Nov;10(6):552. doi: 10.1097/UPJ.0000000000000432.03. Epub 2023 Sep 1. Urol Pract. 2023. PMID: 37747925 No abstract available.
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann AG, Procopio G, Massari F, Zibelman M, Antonyan I, Huseni M, Basu D, Ci B, Leung W, Khan O, Dubey S, Bex A. Pal SK, et al. Among authors: master va. Lancet. 2022 Oct 1;400(10358):1103-1116. doi: 10.1016/S0140-6736(22)01658-0. Epub 2022 Sep 10. Lancet. 2022. PMID: 36099926 Clinical Trial.
389 results